> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-174/
- Published: 2018-04-08T12:00:00.000Z
- Updated: 2026-09-14T23:57:53.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141176

[**Info Collection Extension Sought for Drug GMP Regs**](https://www.fdaweb.com/info-collection-extension-sought-for-drug-gmp-regs/)  
Federal Register notice: FDA submits for OMB approval an information collection extension for “Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals (21 CFR parts 210 and 211).” 04/06/2018

[**FDA Science Board to Meet 4/23**](https://www.fdaweb.com/fda-science-board-to-meet-4-23/)  
Federal Register notice: FDA announces a 4/23 Science Board Advisory Committee to hear a report from CBER and the committee’s Research Program Review Subcommittee. 04/06/2018

[**Comments Sought on Drug Exposure-response Analyses**](https://www.fdaweb.com/comments-sought-on-drug-exposure-response-analyses/)  
Federal Register notice: FDA seeks comments on the drug industry’s use of exposure-response analyses, particularly as it relates to recommendations in a 2003 guidance entitled Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications. 04/05/2018 

[**Guide on Liposome Drug Products**](https://www.fdaweb.com/guide-on-liposome-drug-products/)  
Federal Register notice: FDA makes available a guidance entitled “Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation.” 04/05/2018

[**Aninal Drug Regulations Amended to Reflect Approvals, Etc.**](https://www.fdaweb.com/aninal-drug-regulations-amended-to-reflect-approvals-etc/)  
Federal Register Final Rule: FDA amends the animal drug regulations to reflect recent application-related actions for NADAs and ANADAs. 04/04/2018

[**5 NDAs Withdrawn by FDA**](https://www.fdaweb.com/5-ndas-withdrawn-by-fda/)  
Federal Register notice: FDA withdraws approval of five NDAs because the drug products are no longer marketed. 04/03/2018

[**Editorial, Typographical Corrections in Device Regs**](https://www.fdaweb.com/editorial-typographical-corrections-in-device-regs/)  
Federal Register Final Rule; technical amendment: FDA amends certain medical device regulations to correct editorial issues, such as typographical errors, and to ensure accuracy and clarity in the regulations. 04/03/2018

[**FDA Orders PEG 3350 ANDAs Off Market Due to OTC Switch**](https://www.fdaweb.com/fda-orders-peg-3350-andas-off-market-due-to-otc-switch/)  
Federal Register notice: FDA issues an order withdrawing approval of ANDAs for certain prescription laxatives with the active ingredient polyethylene glycol 3350 because the drug products are misbranded. 04/02/2018

[**Draft 5-Year Plan on Implementing Benefit-Risk Assessments**](https://www.fdaweb.com/draft-5-year-plan-on-implementing-benefit-risk-assessments/)  
Federal Register notice: FDA makes available a draft five-year plan describing its approach to further implement a structured benefit-risk assessment that includes the patient’s voice in drug development and decision-making. 04/02/2018

[**How Industry Can Submit Proposed Guidances**](https://www.fdaweb.com/how-industry-can-submit-proposed-guidances/)  
Federal Register Final Rule; technical amendment: FDA amends its good guidance practices regulation to inform the public on how to electronically submit a draft of a proposed guidance to the agency. 04/02/2018